



**TO: General Acute Care Hospitals and Children’s Hospitals**

**RE: Billing Guidance for Chimeric Antigen Receptor (CAR-T) Cell Treatments**

The Department of Social Services (DSS) is issuing guidance for the billing of Chimeric Antigen Receptor (CAR-T) Cell Treatment when the infusion/administration of the genetically modified cells is performed as part of an authorized inpatient admission.

**Inpatient Hospital**

In order to receive correct reimbursement for CAR-T Cell Treatment when the modified cells are administered as part of an approved inpatient admission, hospitals must bill for the applicable CAR-T biological procedure code on an outpatient hospital claim at the time of harvesting of the blood-derived T lymphocytes for the development of genetically modified autologous CAR-T cells. The reimbursement of the applicable biological procedure code will encompass all the various steps required to collect and prepare autologous CAR-T cells. When billing for CAR-T Cell Treatment, hospitals should append Revenue Center Code (RCC) 0891 – *Special Processed Drugs – FDA Approved Cell Therapy* on the outpatient claim with the applicable procedure code.

<b>Procedure Code</b>	<b>Description</b>
Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti-CD19 CAR T Cells, including leukapheresis and dose preparation procedures, per infusion
Q2042	Tisagenlecleucel, up to 600 million CAR-positive viable T cells,

	including leukapheresis and dose preparation procedures, per therapeutic dose
Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells
C9076	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells

*\*Since many CAR-T cell therapies are being studied, the above list may not include all CAR-T Cell treatment procedure codes. Please refer to CMAP Addendum B for payment information for each applicable biological procedure code.*

When the HUSKY Health member is admitted to the inpatient hospital for the administration/infusion portion of the treatment, the hospital will be reimbursed via the All Patient Refined - Diagnostic Related Group (APR-DRG) for the approved inpatient stay. Since the biological procedure code for CAR-T will be billed as an outpatient claim prior to the inpatient admission, the inpatient claim must not include the biologic procedure code.

**Outpatient Hospital**

When CAR-T Cell Treatment is rendered in the outpatient hospital setting, hospitals must continue to follow the CMAP Addendum B for reimbursement. Hospitals should append RCC 0891 – *Special Processed Drugs – FDA Approved Cell Therapy* with the applicable procedure code.

CMAP's Addendum B for outpatient hospital services can be accessed via the [www.ctdssmap.com](http://www.ctdssmap.com) Web site by selecting the "Hospital Modernization" Web page. CMAP's Addendum B (Excel) is located under "Important Messages – Connecticut Hospital Modernization".

### **Prior Authorization**

No changes have been made to the prior authorization requirements for CAR-T Cell Treatment. PA Forms are available on the HUSKY Health Web site at: <https://portal.ct.gov/husky>. To access the forms, click on *Information for Providers* followed by *Provider Forms* under the *Medical Management* menu item. **Please Note:** A PA request for CAR-T Cell Treatment does not replace the PA for an inpatient admission. Hospitals must request a PA for CAR-T Cell Treatment, as well as a separate PA for the inpatient hospital admission.

CAR-T Cell Treatment policies are also available on the HUSKY Health Web site at: <https://portal.ct.gov/husky>. To access the policies, click on *Information for Providers* followed by *Policies, Procedures and Guidelines* under the *Medical Management* menu item. To access the PA forms, click on *Information for Providers* followed by *Provider Forms* under the *Medical Management* menu item

### **Prior Authorization Submission Process**

For questions regarding the prior authorization process, please contact Community Health Network of CT, Inc. (CHNCT) at 1-800-440-5071, between the hours of 8:00 a.m. and 6:00 p.m.

